Fundraising FoxAbingworth — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Samir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)in
Board seatBali Muralidhar· per SEC Form D
Co-investorsAisling CapitalHealthCapRiverVest Venture PartnersNorwest Venture PartnersNovo HoldingsOmega Funds+1 more
Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team.
BiotechHealthtechSouth San Francisco, US
Kathleen Collins(Director)inLawrence Kong(Executive Officer)inRon Park(President & CEO)inFrancine Gregoire(Chief Scientific Officer)inPriya Parameswaran(Chief Business Officer)in
BoardJayson Punwani(Director)in
Co-investorsBEVCPivotal Life SciencesSR One Capital Management
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.